Previous studies reporting that statin increases coronary artery calcium (CAC) were conducted exclusively on patients with statin as a prevention, regardless of the presence or absence of dyslipidemia. The impact of sex on CAC has not been fully evaluated. We aimed to determine the association of dyslipidemia and sex with CAC using 320-row multi-detector computed tomography (MDCT).
T he presence of calcified plaques in the coronary artery is associated with future adverse coronary events. [1] [2] [3] Statin therapy was proven efficient for the primary and secondary preventions of coronary adverse events 4, 5) through stabilization of unstable plaques and management of low-density lipoprotein (LDL) cholesterol levels. 6, 7) However, it remains to be elucidated whether there is any association between statin and coronary artery calcium (CAC) formation. 8) Recent intravascular ultrasound (IVUS) studies indicated that high-dose statin therapy leads to a reduction in the necrotic core volume, but to an increase in tissue calcification. [9] [10] [11] [12] These IVUS studies were conducted on high-risk patients diagnosed with coronary artery disease (CAD) [9] [10] [11] or STsegment elevation myocardial infarction (STEMI). 12) As those patients received statin therapy regardless of the presence or absence of dyslipidemia, we could not differentiate the effect of statins and dyslipidemia on CAC. Furthermore, the region of interest in IVUS was limited to the proximal coronary vessels, instead of the entire coronary vasculature.
Multi-detector computed tomography (MDCT) provides images of all coronary arteries with a higher specificity of CAC. The efficiency of MDCT remains controversial as some studies reported a significant impact of statin therapy on coronary plaque burden and/or CAC, 13, 14) whereas others reported no significant effect of the treatment. 15, 16) Such discrepancy could be explained in terms of small sample size, binary endpoint on the presence or absence of calcified plaques, and/or CAC assessment based only on the Agatston score of the entire heart.
Women were reported to have smaller coronary plaques and larger coronary artery lumen volumes than men. 17, 18) Although IVUS studies showed lower CAC volumes in the target lesions in women than in men, 19 ) the impact of sex on CAC in the entire coronary artery vasculature has not been fully addressed.
The aim of this study was to determine the impact of Asami, ET AL Figure 1 . Flow chart of the study: among the 356 patients who underwent multi-detector computed tomography (MDCT) during the study period, 97 patients were excluded because of prior stent implantation and 8 patients were excluded because of poor image quality. The remaining 251 patients eligible for the present study included 227 patients with stable angina, 1 patient with unstable angina, 15 patients with silent ischemia, and 8 patients who tested positive for multiple coronary risk factors.
dyslipidemia with/without statin and sex on the CAC and atheroma burden by vessel volumetric analysis using 320-row MDCT in relatively low-risk patients.
Methods
Patient population: This study was conducted on 356 consecutive patients evaluated for CAD by coronary CT angiography using 320-row MDCT (Aquilion ONE; Toshiba Medical Systems, Nasu, Japan) between January and April 2012 in our institution. They were referred to our hospital due to symptoms of angina, abnormal electrocardiogram or echocardiographic findings at rest or stressed, and/or suspected CAD based on several coronary risk factors. This study was conducted in accordance with the Declaration of Helsinki. The physicians obtained written informed consent from each patient. Computed tomography protocol: Three hours before MDCT, any patients with a heart rate (HR) > 65 beats/ minute received 20 mg of oral metoprolol (Novartis Pharma K.K., Tokyo, Japan). If the HR remained > 60 beats/minute prior to the scan, 0.125 mg/kg of an ultrashort acting intravenous β-blocker (landiolol, Ono Pharmaceutical Co., LTD., Osaka, Japan) was administered to further reduce the HR. 20) Immediately before image acquisition, almost all patients received 0.3 mg nitroglycerin sublingual. Scan parameters were as follows: a collimation of 320 rows × 0.5 mm, rotation time of 350-400 ms, and tube voltage of 120 kV. The tube current (270-400 mA) was selected according to the standard deviation of the noise level measured on the CT projection radiograph. Electrocardiogram-gated non-enhanced scans were obtained, followed by contrast-enhanced scans with iopamiron 370 mg/mL (Bayer Schering Pharma, Osaka, Japan) injected at a speed of 4.0-5.0 mL/second over 10 seconds. The scanner's "arrhythmia rejection" software automatically removed irregular beatings using the multi-segment acquisition technique.
21) The Phase-NAVI scanner software (Toshiba Medical Systems, Nasu, Japan) automatically determined the appropriate cardiac phase with minimum cardiac motion for the MDCT axial image reconstruction. All data acquired with 0.5 mm-thick slices were reconstructed using a standard kernel of FC04.
The QAngio CT software (QAngio CT 1.3.8; Medis Medical Imaging Systems, Leiden, the Netherlands) was used for the quantitative CT analysis (Supplemental Figure 1) . 22) The scans presenting insufficient image quality because of motion artifacts were excluded from the volumetric analysis. Experienced observers blinded to the clinical data assessed MDCT datasets. Definition of the CT parameters: All coronary vessels with a diameter !1.5 mm were included in the analysis. The contour and lumen were traced using semi-automated algorithms. The coronary plaque volume was calculated as ASSOCIATION OF DYSLIPIDEMIA AND SEX WITH CAC the sum of voxels between the vessel wall and lumen contours. The calcification volume was calculated as the sum of the voxels positioned within the coronary plaque with a value above the threshold of 130 Hounsfield units predefined with the non-enhanced scans, according to the Agatston approach. 23) The percent atheroma volume (PAV) and percent calcium volume (PCV) were calculated using the following equations: PAV = (total vessel wall volume -total lumen volume)/total vessel wall volume × 100% PCV = total calcium volume/total vessel wall volume × 100%
For the volumetric analysis, the entire coronary artery tree was divided into the following four vessels: left main coronary artery (LMCA), left anterior descending artery (LAD), left circumflex artery (LCx), and right coronary artery (RCA). The LMCA extended from the aorta ostia to the bifurcation between the LAD and the LCx. The lesions were identified by the software, which measured their minimal lumen area and minimal lumen diameter. The percent area stenosis was calculated as the minimum area over the mean proximal and distal reference area. The percent diameter stenosis was calculated as the minimum diameter over the mean proximal and distal reference diameters. The proximal and distal reference values were defined in healthy segments adjacent to the Asami, ET AL Values are mean ± standard deviation where appropriate. PAV = (total vessel wall volume -total lumen volume)/total vessel wall volume × 100%; PLV = total lumen volume/total vessel wall volume × 100%; PCV = total calcium volume/total vessel wall volume × 100%. MLA indicates minimal lumen area; MLD, minimal lumen diameter; PLV, percent lumen volume; %AS, percent lumen area stenosis; and %DS, percent lumen diameter stenosis.
lesions. Significant stenosis was defined as lesions with percent diameter stenosis > 50%. The remodeling index was defined as the outer vessel area at the site of maximum luminal narrowing over the mean areas of the proximal and distal reference sites.
24)
Definition of the coronary risk factors: The definition of the coronary risk factors are available in the supplementary data online.
Statistical analysis:
The continuous variables were expressed as the mean value ± standard deviation and compared using two-tailed unpaired t-tests. The categorical variables were expressed as numbers and percentages and compared using two-tailed Chi-square tests. Linear mixed models were constructed in which continuous outcomes, such as PAV and PCV, were included as linear response variables. All clinically relevant explanatory variables were included in the univariate model and/or the multivariable full model (Supplemental Table) . Among them, the independent predictors were identified with the minimum Akaike's Information Criterion using the backward stepwise approach. The LAD, LCx, RCA, and LMCA were included in all models as a random intercept. As approximately 62.5% of the vessels (n = 628) had 0% PCV, a second model was constructed using the presence or absence of CAC as a binary response variable to ensure robustness. All statistical analyses were performed with the R software version 3.2.3 (R Foundation for Statistical Computing, Vienna, Austria), and all P < 0.05 were considered statistically significant.
Results
Study population: During the study period, MDCT was performed in 356 patients at our hospital (Figure 1 ). Of these, we excluded 97 patients who had coronary revascularization by percutaneous coronary intervention and/or coronary artery bypass grafting as well as 8 patients due to poor MDCT image quality. According to these exclusion criteria, 251 patients (1004 vessels) underwent volumetric analysis. Most patients (90.8%) presented symptoms of stable angina pectoris, whereas the few asymptomatic patients had silent ischemia or were positive for multiple coronary risk factors.
The baseline characteristics are presented in Table I . The mean age was 65.3 ± 12.6 years, and 158 patients (62.9%) were men. The Canadian Cardiovascular Society grading system indicated that most of the 228 patients diagnosed with angina pectoris were of grade 1 (62.2%) or grade 2 (25.5%).
A total of 174 patients had hypertension (69.3%), and 159 patients (91.4%) received at least one type of anti-hypertensive drugs, such as a calcium channel blocker, an angiotensin-converting enzyme inhibitor, an angiotensin II receptor blocker, or a β-blocker. Most patients also presented dyslipidemia (64.9%), and about a third (29.5%) followed a statin treatment. In contrast, diabetes mellitus was diagnosed only in 67 (26.7%) patients, and 13 (5.2%) cases required insulin treatment. Finally, CKD was also a minor complication (25.5%), and only 5 patients (2.0%) required maintenance hemodialysis.
There was no significant difference between men and women, except for higher values of HbA1c (6.03% ± 1.17% versus 5.68% ± 0.70%, P = 0.003), fasting blood glucose (121.8 ± 46.8 mg/dL versus 108.4 ± 26.0 mg/dL, P = 0.004), triglyceride (136.8 ± 99.0 mg/dL versus 111.4 ± 80.3 mg/dL, p = 0.03), and current smoker (22.2% versus 6.5%, P = 0.002) in men. Detailed morphometric analysis of the coronary vessels: Volumetric analysis indicated that 40.6% of the 1004 vessels had no calcium deposit, and mean PCV was 5.67% ± 11.6% (Table II) . In contrast, mean PAV was 44.7% ± 9.93%, and 31.1% of the patients exhibited a percent lumen diameter stenosis > 50%. We excluded the parameters that were strongly correlated factors and those missing several values. The best model was selected using the stepwise approach. AIC indicates Akaike's Information Criterion. Other abbreviations as in Table I .
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Univariate and multivariable analyses:
The following factors were positively associated with both the PAV and PCV: age, hypertension under medication, diabetes mellitus (with/without insulin), dyslipidemia without statin therapy, and CKD (with/without hemodialysis), but negatively associated with a family history of CAD (Table III) . On the other hand, only the PAV was associated negatively with women and positively with the level of high sensitivity C-reactive protein (hs-CRP), whereas only the PCV was negatively associated with dyslipidemia controlled with statin. Multivariable analyses using the minimum Akaike's Information Criterion model identified age, diabetes mellitus (with/without insulin), dyslipidemia without statin, current smoker, and hs-CRP as significant correlation factors of higher PAV (Table III, Figures 2-5). On the other hand, the independent predictors of a higher PCV were age, hypertension under medication, diabetes mellitus (with/without insulin), dyslipidemia without statin, CKD (with/without hemodialysis), and current smoker (Table III, Figure 2 , and Supplemental Figures 2, 4-7) . Dyslipidemia as a predictor of an increasing atheroma volume: Dyslipidemia without statin was identified as an independent predictor of higher PAV (partial regression coefficient [PRC]: 5.19, 95% confidence interval [CI]: 3.29 to 7.09, P < 0.001) and higher PCV (PRC: 2.59, 95% CI: 0.83 to 4.34, P = 0.004) (Table III , Supplemental Figures 3A, B) . However, there was no significant correlation between dyslipidemia controlled with statins and higher PCV (PRC: -1.09, 95% CI: -2.82 to 0.65, P = 0.22; Table III ). Statin therapy was associated with significantly lower PCV among dyslipidemia patients (PRC [with statin relative to without statin]: -3.07, 95% CI: -4.73 to -1.41, P < 0.001) ( Figure 2B ). Similar results were obtained using binomial or continuous response variables. The prevalence of CAC was significantly higher in the dyslipidemia patients not taking statin than in the patients not diagnosed with dyslipidemia (odds ratio: 2.60, 95% CI: 1.74 to 3.88, P < 0.001), whereas there was no correlation when dyslipidemia was controlled with statins (odds ratio: 1.36, 95% CI: 0.94 to 1.99, P = 0.11; Table  IV) .
Women as a predictor of a low atheroma volume:
Women were an independent predictor of low PAV (PRC: -2.87, 95% CI: -4.54 to -1.20, P = 0.001; Figure 2C ). Although women tended have lower PCV than men in the univariate analysis (PRC: -1.32, 95% CI: -2.78 to 0.14, P ASSOCIATION OF DYSLIPIDEMIA AND SEX WITH CAC = 0.08; Figure 2D ), there was no significant correlation between sex and PCV after adjusting the confounds.
Discussion
This study investigated the factors associated with higher PCV and PAV by volumetric analysis using 320-row MDCT in relatively low-risk patients. The main findings of this study were as follows: 1) PCV and PAV are similar in patients without dyslipidemia or with dyslipidemia controlled by statin therapy, but they are significantly higher in dyslipidemia patients not taking statin than in those without dyslipidemia. 2) Women are not associated with higher PCV after adjusting the confounders, but is an independent predictor of lower PAV.
Several IVUS studies suggested that statin therapy was associated with an increase in CAC deposition. [9] [10] [11] [12] 25, 26) However, these studies were conducted on high-risk patients, such as those with STEMI 12) or clinical indications of coronary angiography. [9] [10] [11] 25, 26) Thus, these patients were likely to receive statin therapy regardless of the presence or absence of dyslipidemia. In contrast, our study group included relatively low-risk patients in comparison with aforementioned studies and compared CAC deposition among patients under statin therapy, those with dyslipidemia but not receiving statin therapy, and those without dyslipidemia. This study measured similar CAC volumes in 74 dyslipidemia patients taking statins (29.4%) and 88 patients without dyslipidemia (35.1%). On the other hand, 89 dyslipidemia patients not receiving statin therapy (35.5%) had higher CAC deposition than those without dyslipidemia.
In the Integrated Biomarkers and Imaging Study-4 (IBIS-4) trial, Räber et al. reported that statin therapy is associated with the regression of coronary atherosclerosis and the progression of CAC deposition in the non-infarctrelated arteries of patients diagnosed with STEMI. 12) Moreover, a sub-study of the Study of coronary Atheromaby in Travascular Ultrasound: the effect of Rosuvastatin vs. atorvastatiN (SATURN) trial indicated that intensive statin therapy may reduce the fibro-fatty plaques and increase the amount of dense calcium tissue. 11) These intravascular imaging studies were conducted in a highrisk population and all patients received statin therapy according to the study protocol. In this study, statin therapy was associated with significantly lower PCV. In contrast, there was an impact on dyslipidemia patients without statin, who had significantly higher LDL cholesterol levels, on higher PCV. Considering the similar sample sizes of the group without dyslipidemia, the dyslipidemia group taking statins, and the dyslipidemia group not taking statins, we speculate that a statin therapy has a lower impact on the accumulation of CAC than dyslipidemia. It remained unclear whether the reduction in LDL cholesterol levels using statin therapy may reduce CAC deposition. Future large-scale studies on low-risk patients with no clinical indication for statin therapy are needed to discriminate the impact of statins and dyslipidemia on CAC.
Statins are known to inhibit the proliferation of vascular smooth muscle cells (VSMCs), which suppresses the narrowing of the vascular lumen. 27) However, they also induce apoptosis in VSMCs, one of the most important roles in the process of vascular calcification. 27, 28) Furthermore, the apoptosis of VSMCs was related to fatty degen-Asami, ET AL eration, inflammatory cytokines, and nitric oxide affected by oxidized LDL cholesterol. 29) Theoretically, statin therapy may increase the accumulation of CAC in addition to the effect of higher LDL cholesterol. Thus, statin may accelerate CAC deposition in relatively high-risk patients receiving high-dose statin therapy. However, the presence of dyslipidemia per se has a greater impact on CAC in relatively low-risk patients.
Several IVUS studies identified sex as a predictive factor of coronary plaque volume, but the impact of sex on CAC has not been fully assessed. 30) The relationship between sex and plaque morphology, investigated by MDCT, remains controversial. 31, 32) Although women were identified as the strongest predictor for the absence of calcified plaque in one study, 31) the other study detected no effect on the presence of calcified plaque. 32) However, these studies did not include a quantitative analysis of CAC. The present study identified women as an independent predictor of lower PAV, but sex did not influence PCV. It is well known that men possess a greater atheroma burden, more eccentric atheroma, and more diffuse epicardial endothelial dysfunction than women. 33) These differences are mainly explained by the protective effects of estrogen against coronary plaques in women. 34) Such protective effects may suppress calcium accumulation in the coronary artery plaques. Study limitations: This study has a few limitations. First, this was an observational cross-sectional study. As the patients were not randomly allocated to statin therapy, we could not rule out the presence of unmeasured confounders. Thus, an indication of the present study was a strong confounding factor for the evaluation of statin effects. Second, because of the cross-sectional study design, we could not assess the duration of statin therapy and the cumulative effect of statins on CAD. Finally, although the number of patients in our study was comparable with other imaging studies, our sample size was insufficient, In addition, all subjects were drawn from a single center. Thus, further larger studies are warranted.
Conclusions
Calcium accumulation in the coronary arteries was associated with dyslipidemia patients without statin, but there was no significant association between CAC and those with statin in relatively low-risk patients. These findings could be translated into hypotheses, which should be tested in future prospective studies. Women were not associated with CAC but were identified as an independent predictor of lower atheroma burden.
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